Literature DB >> 1636240

Complications of bacillus Calmette-Guérin immunotherapy.

D L Lamm1.   

Abstract

Knowing when to give and when to withhold BCG will prevent most complications, but even when all precautions are taken, some complications will occur. The initial step in the treatment of infectious complications is the use of isoniazid. Routine prophylactic isoniazid should not be given, as animal studies have confirmed that immune stimulation, and presumably antitumor activity, can be inhibited by isoniazid prophylaxis. However, when cystitis persists more than 2 days or is so severe that it does not respond to symptomatic treatment, isoniazid 300 mg daily is used to control the symptoms, prevent progressive infection, and avoid the overgrowth of BCG, which can result in excessive organisms and suppression of the immune response. If symptoms progress despite isoniazid treatment or do not begin to abate within 1 to 2 weeks, rifampicin 600 mg daily is added. Rifampicin is given from the beginning in patients with potentially severe extravesical BCG infection such as pneumonitis, hepatitis, or nephritis. In patients with symptoms such as fever, malaise, or bladder irritation that respond within a few days, it generally is necessary to continue antitubercular antibiotics for only 2 weeks. Those with extravesical infection and those who do not respond promptly to treatment are treated for 3 months, and those with severe or deep-seated infection are treated for 6 months. The current recommendation for the treatment of sepsis after BCG administration, based on limited clinical experience and controlled animal experimentation, is to use isoniazid and rifampicin plus prednisolone 40 mg daily.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1636240

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  37 in total

1.  Rapid identification of mycobacteria and drug-resistant Mycobacterium tuberculosis by use of a single multiplex PCR and DNA sequencing.

Authors:  Ailyn C Pérez-Osorio; David S Boyle; Zachary K Ingham; Alla Ostash; Romesh K Gautom; Craig Colombel; Yolanda Houze; Brandon T Leader
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  Detection of bacillus Galmette-Guérin (Mycobacterium bovis BCG) DNA in urine and blood specimens after intravesical immunotherapy for bladder carcinoma.

Authors:  Argyrios Siatelis; Dimitra P Houhoula; Joseph Papaparaskevas; Dimitrios Delakas; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

3.  Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy.

Authors:  Vasiliki Delimpoura; Konstantinos Samitas; Ioannis Vamvakaris; Eleftherios Zervas; Mina Gaga
Journal:  BMJ Case Rep       Date:  2013-10-10

4.  PCR identification of Mycobacterium bovis BCG.

Authors:  E A Talbot; D L Williams; R Frothingham
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

5.  A case of Pott's disease with epidural abscess and probable cerebral tuberculoma following Bacillus Calmette-Guérin therapy for superficial bladder cancer.

Authors:  Colin B Josephson; Saleh Al-Azri; Daniel J Smyth; David Haase; B Lynn Johnston
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

6.  A case of BCG sepsis with bone marrow and liver involvement after intravesical BCG instillation.

Authors:  B Dederke; E O Riecken; T Weinke
Journal:  Infection       Date:  1998 Jan-Feb       Impact factor: 3.553

7.  Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladder.

Authors:  Chang-Ho Ryan Choi; Sang Oh Lee; Geoff Smith
Journal:  BMJ Case Rep       Date:  2014-05-08

8.  Specific differentiation between Mycobacterium bovis BCG and virulent strains of the Mycobacterium tuberculosis complex.

Authors:  J Magdalena; P Supply; C Locht
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

9.  Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin.

Authors:  Aliye Soylu; Ali T Ince; Hakan Polat; Nurgul Yasar; Aydin Ciltas; Selvinaz Ozkara; Ali I Tasci
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-04-15       Impact factor: 3.944

10.  Prosthetic Joint Infection due to Mycobacterium bovis after Intravesical Instillation of Bacillus Calmette-Guerin (BCG).

Authors:  Eric Gomez; Tom Chiang; Ted Louie; Madhavi Ponnapalli; Robert Eng; David B Huang
Journal:  Int J Microbiol       Date:  2009-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.